BUSINESS Granules India completes cGMP audit at Chantilly site with four FDA observations Apr 4, 2026
Granules India subsidiary receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets Dec 22, 2025
Granules India subsidiary receives five procedural observations after US FDA GMP inspection Dec 19, 2025
Granules India Q1 Results: Revenue jumps 2.56% YoY to Rs 1,210.11 crore, net profit falls 16.37% YoY Aug 12, 2025
Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection Aug 1, 2025